Amneal Pharmaceuticals Inc

AMRX

Equity

ISIN null / Valor 41368351

NASDAQ (2025-11-18)

USD 11.57-0.09%

Amneal Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Amneal Pharmaceuticals Inc. is a U.S.-based pharmaceutical company that specializes in the development, manufacturing, and distribution of generic and specialty pharmaceutical products. The company offers a broad portfolio of medications, including an FDA-approved over-the-counter generic equivalent for Narcan® (Naloxone HCl) Nasal Spray, which is used to counteract opioid overdoses. This product is available without a prescription under the Amneal brand at select major U.S. pharmacies. Amneal's business model focuses on providing high-quality, affordable medications to meet the needs of patients and healthcare providers.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In Q2 2025, Amneal Pharmaceuticals Inc achieved a net revenue of $725 million, marking a 3% increase compared to $702 million in Q2 2024. Specialty net revenue surged by 23%, driven by key branded products such as CREXONT®, RYTARY®, and UNITHROID®.

Enhanced Profitability

The company reported a GAAP net income of $22 million for the second quarter, up from $6 million in the same period last year. Adjusted EBITDA rose by 13% to $184 million, and diluted income per share increased to $0.07 from $0.02, reflecting higher operating income and favorable foreign exchange rates.

Raised Full-Year Guidance

Amneal raised its full-year 2025 financial guidance, increasing the adjusted EBITDA forecast to between $665 million and $685 million and the adjusted diluted EPS to between $0.70 and $0.75. Operating cash flow guidance was also elevated, ranging from $275 million to $305 million.

Debt Refinancing Success

The company successfully completed a comprehensive debt refinancing on August 1, 2025, securing $2.1 billion in new Term B loans and issuing $600 million in senior secured notes due 2032. This refinancing strategy has substantially reduced interest costs and extended debt maturities to 2032, strengthening Amneal's capital structure.

Summarized from source with an LLMView Source

Key figures

38.9%1Y

417%3Y

182%5Y

Performance

34.0%1Y

51.1%3Y

53.0%5Y

Volatility